Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients
Status:
Unknown status
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
Null Hypothesis:
There is no significant difference in the incidence of CMV infection when using oral
valganciclovir or ganciclovir as prophylactic anti-viral therapy.
Alternate Hypothesis:
There exists a significant difference in the incidence of CMV infection when oral
valganciclovir is used for CMV prophylaxis rather than oral ganciclovir. A formal hypothesis
to be tested should be defined.